Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in BHD-Associated or Sporadic Chromophobe Kidney Cancer
NCT02504892Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in renal cell carcinoma (RCC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 1 year. Started Jul 2015; status: terminated.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02504892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504892.